Meeting
2019 ASCO Annual Meeting
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
Authors
Meredith Pelster
The University of Texas MD Anderson Cancer Center, Houston, TX
Meredith Pelster , Stephen K. Gruschkus , Roland Bassett , Dan S. Gombos , Michael Shephard , Liberty Posada , Maura Glover , Adi Diab , Patrick Hwu , Sapna Pradyuman Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01585194
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9522)
DOI
10.1200/JCO.2019.37.15_suppl.9522
Abstract #
9522
Poster Bd #
93
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
First Author: Thaïs M.L. Tong
Poster
2020 ASCO Virtual Scientific Program
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
First Author: James Lin Chen
Poster
2017 ASCO Annual Meeting
The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM).
First Author: Sapna Pradyuman Patel
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain